

# **The Clinical Frontier of Oncology: A Comprehensive Analysis of Liquid Biopsy for the Detection and Management of Molecular Residual Disease**

**Li Lei, PhD**

**Bioinformatics Scientist in Lawrence Berkeley National Lab**

## **06/28/2025**

## **Abstract**

In the evolving landscape of oncology, liquid biopsy is emerging as a transformative tool for the detection of Minimal Residual Disease (MRD), offering a non-invasive method to identify the minute number of cancer cells that persist after treatment and often precede clinical relapse. By analyzing circulating tumor DNA (ctDNA) from a simple blood draw, these highly sensitive assays can detect MRD with remarkable lead time over conventional imaging, enabling a more dynamic and real-time assessment of treatment efficacy. This approach has demonstrated significant prognostic value across a spectrum of solid tumors—including colorectal, lung, and breast cancer—and hematological malignancies, where the presence of ctDNA post-treatment is a strong predictor of recurrence. While challenges in standardization, analytical sensitivity, and clinical validation remain, the ongoing integration of advanced bioinformatics and multi-omic strategies is paving the way for liquid biopsy-guided MRD assessment to become a cornerstone of personalized cancer care, allowing for early intervention and tailored therapeutic strategies to improve patient outcomes.

## **Section 1: Foundational Principles of Liquid Biopsy and Molecular Residual Disease**

The management of cancer is undergoing a profound transformation, driven by technologies that allow for the detection and characterization of tumors with unprecedented sensitivity. Central to this evolution are the concepts of liquid biopsy and molecular residual disease (MRD). Together, they represent a paradigm shift away from anatomical assessment toward a more dynamic, molecular understanding of cancer. This section establishes the fundamental scientific and clinical principles that underpin this approach, defining the core concepts, describing the key biological analytes shed by tumors, and explaining why the detection of subclinical disease is a critical objective in modern oncology.

### **1.1 The Paradigm of Liquid Biopsy: Moving Beyond the Tissue Standard**

A liquid biopsy is a laboratory test performed on a sample of bodily fluid—most commonly blood, but also potentially urine, saliva, or cerebrospinal fluid (CSF)—to detect and analyze cancer-derived biomarkers.1 This technique offers a minimally invasive or entirely non-invasive alternative to the traditional "gold standard" of cancer diagnosis: the surgical tissue biopsy.3 While tissue biopsy remains indispensable for the initial diagnosis and histological classification of a tumor, its limitations are significant and well-documented. The procedure is invasive, carrying inherent risks of pain, infection, and bleeding, and can involve substantial cost and recovery time.6

Perhaps more critically from a biological standpoint, a tissue biopsy provides only a single, localized snapshot of a tumor at one specific moment. This is often insufficient to capture the full spectrum of intratumoral heterogeneity—the complex genetic and molecular diversity that exists within a single tumor and between different metastatic sites.6 A tumor is not a monolithic entity; it is an evolving ecosystem of distinct subclones. A biopsy needle may sample one region while missing another that harbors key resistance mutations. This sampling bias can lead to an incomplete and potentially misleading molecular profile, impacting treatment decisions.

Liquid biopsy fundamentally overcomes this limitation by providing a systemic, rather than localized, view of the disease. As biomarkers from all tumor sites—both primary and metastatic—are shed into the bloodstream, a single blood draw can capture a more comprehensive and representative sample of the cancer's complete mutational landscape.6 This is a particularly powerful advantage in metastatic disease, where biopsying every lesion is impractical or impossible.6 Furthermore, the non-invasive nature of liquid biopsy enables longitudinal monitoring through repeated sampling over time.1 This dynamic tracking of tumor evolution, response to therapy, and the emergence of resistance mechanisms is a capability that is simply not feasible with invasive tissue biopsies and is central to the promise of truly personalized medicine.7 This accessibility effectively democratizes access to the tumor's genetic information, overcoming the physical and logistical barriers of tissue biopsy for patients who are too frail for an invasive procedure or have anatomically inaccessible tumors.3

### **1.2 Analytes in Circulation: A Survey of Key Biomarkers**

The power of liquid biopsy stems from its ability to detect and analyze various tumor-derived components circulating in bodily fluids. Each analyte offers a unique window into the tumor's biology.

**Circulating Tumor DNA (ctDNA)** is the most widely studied and clinically advanced liquid biopsy analyte. It consists of small fragments of DNA, typically around 167 base pairs in length, that are released into the bloodstream when tumor cells die through processes like apoptosis and necrosis.4 These fragments are veritable molecular echoes of the parent tumor, carrying its specific genetic and epigenetic alterations, including single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), and DNA methylation patterns.15 A crucial characteristic of ctDNA is its short biological half-life, which is on the order of hours.17 This makes it a highly dynamic biomarker that provides a real-time reflection of the current tumor burden and activity, rather than a historical record.

**Circulating Tumor Cells (CTCs)** are intact, viable tumor cells that have detached from a primary or metastatic tumor and entered the circulatory system.4 CTCs are much rarer and more technically challenging to isolate from blood than ctDNA.19 However, they offer unique biological information that fragmented DNA cannot. As whole cells, CTCs can be analyzed at the single-cell level to provide genomic, transcriptomic (gene expression), and proteomic (protein) information.10 They can even be cultured in some cases, providing invaluable models for studying the mechanisms of metastasis and testing drug sensitivity.19

Beyond these two primary analytes, a host of **Emerging Analytes** are expanding the capabilities of liquid biopsy:

* **Extracellular Vesicles (EVs) and Exosomes:** These are microscopic, membrane-bound particles secreted by cells. They act as biological packages, carrying a cargo of proteins, RNA, and DNA that reflects their cell of origin. Their protective membrane makes them stable carriers of tumor-specific information in the bloodstream.12  
* **Cell-Free RNA (cfRNA) and Circulating Tumor RNA (ctRNA):** Unlike DNA, which is largely static, RNA is dynamically expressed and provides a snapshot of active biological processes. Analyzing ctRNA can reveal information about gene expression patterns, potentially identifying cancer subtypes and tissue of origin with greater specificity than DNA alone.20  
* **Tumor-Educated Platelets (TEPs):** Platelets can absorb RNA and proteins from tumor cells, which alters their own molecular profile. This "education" process makes platelets a potential, though still experimental, source of cancer biomarkers.12  
* **Methylation Patterns:** Cancer development is often associated with aberrant DNA methylation. These cancer-specific methylation patterns are preserved in ctDNA and can be detected in blood. This epigenetic information is highly valuable for both cancer detection and identifying the tumor's tissue of origin, a principle heavily utilized in multi-cancer early detection (MCED) tests.15

Table 1 provides a comparative overview of the primary liquid biopsy analytes.

**Table 1: Comparison of Liquid Biopsy Analytes for MRD Detection**

| Analyte | Biological Source/Form | Typical Half-life | Relative Abundance in Blood | Information Provided | Key Detection Challenges |
| :---- | :---- | :---- | :---- | :---- | :---- |
| **ctDNA** | Fragmented DNA from apoptotic/necrotic tumor cells | \< 2 hours | Variable, but more abundant than CTCs | Genomic (mutations, CNVs), Epigenetic (methylation), Fragmentomics | Very low fraction of total cfDNA, requiring highly sensitive assays; background noise from CHIP. |
| **CTCs** | Intact, viable tumor cells | 1-2.4 hours | Extremely rare (\<1 to \<50 per 7.5 mL blood) | Genomic, Transcriptomic, Proteomic, Functional (can be cultured) | Rarity makes isolation and enrichment difficult; heterogeneity of cell properties. |
| **EVs/Exosomes** | Membrane-bound vesicles secreted by cells | Hours to days | Abundant | Genomic, Transcriptomic, Proteomic, Metabolomic | Lack of standardized isolation methods; distinguishing tumor-derived EVs from normal EVs. |
| **cfRNA/ctRNA** | RNA fragments, often within EVs or protein complexes | Minutes to hours | Highly variable, generally low | Transcriptomic (gene expression, fusions) | RNA is less stable than DNA; requires specialized collection and processing. |
| **Methylation Patterns** | Epigenetic marks on ctDNA fragments | Same as ctDNA | Same as ctDNA | Epigenetic (gene regulation, tissue of origin) | Requires specialized techniques like bisulfite sequencing; interpretation can be complex. |

### **1.3 The Clinical Significance of Minimal Residual Disease (MRD): The Subclinical Reservoir for Relapse**

Minimal Residual Disease, now more commonly termed Measurable Residual Disease (MRD), refers to the small number of cancer cells that remain in the body during or after definitive treatment.24 These cells are present at levels far below the detection threshold of conventional methods like radiographic imaging (CT, PET scans) or standard laboratory tests.26 The shift in terminology from "minimal" to "measurable" reflects the reality that these cells, while invisible to older techniques, are now being precisely quantified by a new generation of highly sensitive assays capable of detecting as few as one cancer cell among one million normal cells.24

The presence of MRD after therapy is the single most powerful predictor of subsequent disease relapse across a wide range of cancers.26 An MRD-positive status is a definitive indicator that the treatment was not fully curative and that a subclinical reservoir of viable, often treatment-resistant, tumor cells persists. These cells are the seeds from which a future clinical recurrence will grow.28 Conversely, achieving a deep, MRD-negative state is strongly associated with prolonged remission and improved overall survival.27

This powerful prognostic information is increasingly being used to guide critical clinical decisions. This represents a fundamental shift in the goals of cancer therapy. Historically, remission in solid tumors was defined anatomically—the disappearance of tumors on an imaging scan. Liquid biopsy for MRD redefines this concept at a molecular level. A patient can now be in "radiographic remission" yet simultaneously have a "molecular relapse" (i.e., be MRD-positive).26 The new therapeutic goal is therefore not just to achieve an anatomical response, but to achieve and maintain MRD negativity, a much deeper and more meaningful measure of treatment success. This has been the standard of care in hematological malignancies like acute lymphoblastic leukemia (ALL) for years and is now becoming the target in solid tumors.25

The clinical applications of MRD status fall into two main categories:

* **Treatment Intensification:** For a patient who is MRD-positive after treatment, the prognosis is poor if no further action is taken. This result can prompt clinicians to intensify or change therapy—for instance, by administering additional cycles of chemotherapy, switching to a different drug, or proceeding to a potentially curative stem cell transplant—in an effort to eradicate the remaining disease before it can cause a clinical relapse.17  
* **Treatment De-escalation:** For a patient who is robustly MRD-negative, the risk of recurrence is very low. This information could be used to de-escalate treatment, allowing these likely-cured patients to be spared the toxicity, side effects, and financial burden of unnecessary adjuvant therapy.17

## **Section 2: The Technological and Bioinformatic Engine of MRD Detection**

The ability to detect MRD relies on finding an infinitesimal tumor-derived signal within a sea of normal biological material. This search for the "needle in a haystack" is made possible by a combination of ultra-sensitive molecular technologies and sophisticated bioinformatic pipelines designed to amplify the signal while suppressing the noise. The success of any MRD test depends not on a single component, but on the seamless integration of a complex system encompassing sample handling, laboratory chemistry, and computational analysis.

### **2.1 Molecular Detection Technologies: Assays for Finding the "Needle in a Haystack"**

Two main classes of technology dominate the MRD detection landscape: polymerase chain reaction (PCR) and next-generation sequencing (NGS).

#### **2.1.1 PCR-Based Methods: High Sensitivity for Known Targets**

Droplet digital PCR (ddPCR) is a refined version of conventional PCR that provides absolute quantification of DNA molecules. The technique works by partitioning a single sample into thousands or millions of microscopic water-in-oil droplets, such that each droplet contains either one or zero target DNA molecules.16 PCR amplification then occurs within each individual droplet. By counting the number of fluorescent "positive" droplets versus "negative" ones, the assay can calculate the precise starting concentration of the target sequence without the need for a standard curve.16

The performance of ddPCR is characterized by its high sensitivity, with reported limits of detection (LOD) often reaching a variant allele frequency (VAF) of 0.1% to 0.01%.16 It is also relatively cost-effective and offers a rapid turnaround time.16 However, its primary limitation is its low multiplexing capacity. A ddPCR assay is designed to detect a specific, pre-defined mutation. While exceptionally effective for tracking a few known hotspot mutations (e.g.,

*KRAS* mutations in pancreatic cancer or *EGFR* mutations in lung cancer), it is ill-suited for the comprehensive MRD assessment required for tumors with diverse or unknown mutational profiles. This makes it a less preferred approach for broad MRD detection in most solid tumors.16

#### **2.1.2 Next-Generation Sequencing (NGS): The Power of Massively Parallel Analysis**

NGS has become the dominant technology for MRD analysis due to its ability to sequence millions of DNA fragments simultaneously, enabling the detection of a wide array of mutations across numerous genes in a single run.16 Two main NGS strategies are employed:

* **Amplicon-Based NGS:** This method uses targeted PCR to amplify specific genomic regions of interest before sequencing. This approach can achieve extremely high sequencing depth on the selected targets, which is crucial for detecting rare variants. To improve accuracy, advanced techniques like **Tagged-Amplicon Deep Sequencing (TAm-Seq)** incorporate unique molecular identifiers (UMIs) to computationally correct for PCR and sequencing errors.22 The primary limitations are the potential for amplification bias, where certain fragments are amplified more efficiently than others, and the fact that analysis is restricted to the pre-selected amplified regions.16  
* **Hybrid Capture-Based NGS:** This method uses synthetic, biotin-labeled DNA or RNA probes (or "baits") that are designed to be complementary to specific genomic regions of interest. These baits are mixed with the cfDNA sample, where they hybridize to their target sequences. The bait-DNA complexes are then "captured" using magnetic beads, enriching the sample for the desired regions, which are subsequently sequenced.35 This approach allows for much broader genomic coverage than amplicon-based methods and is adept at detecting various types of alterations, including SNVs, indels, CNVs, and complex rearrangements.15  
  **CAncer Personalized Profiling by Deep Sequencing (CAPP-Seq)** is a pioneering hybrid-capture method that has been successfully adapted for MRD detection.36 Further refinements like  
  **PhasED-Seq** enhance sensitivity by leveraging information from multiple mutations that occur on the same original DNA fragment (phased variants).32

### **2.2 Assay Strategies: Tumor-Informed vs. Tumor-Agnostic Approaches**

The application of NGS technology to MRD detection has given rise to two distinct strategic philosophies, each with its own clinical trade-offs between sensitivity, speed, and accessibility.

#### **2.2.1 Tumor-Informed (or Bespoke/Personalized) Assays**

The tumor-informed approach is a two-step process that prioritizes maximum sensitivity. First, a sample of the patient's primary tumor tissue is subjected to comprehensive genomic sequencing, typically whole-exome sequencing (WES), to identify a unique signature of 16 to several hundred clonal somatic mutations.18 In the second step, a personalized MRD panel is designed specifically to track these patient-specific mutations in subsequent plasma samples using an ultra-sensitive multiplex PCR or hybrid-capture NGS assay.38 The

**Natera Signatera** assay is a leading commercial example of this strategy, tracking a set of 16 clonal variants for each patient.18

The primary advantage of this bespoke strategy is its superior sensitivity and specificity. By tracking multiple clonal mutations simultaneously, the probability of detecting the faint MRD signal is mathematically increased. Furthermore, because the assay is searching only for mutations confirmed to be present in the tumor, it inherently filters out biological noise from non-tumor sources like clonal hematopoiesis (CHIP), a major confounding factor in ctDNA analysis.18 The main disadvantages are logistical. This approach requires an available and adequate tumor tissue sample, and the initial assay design process results in a longer turnaround time for the first result—often four to six weeks.38 This delay can be clinically challenging, as decisions about adjuvant therapy often need to be made within a few weeks of surgery.17

#### **2.2.2 Tumor-Agnostic (or Tumor-Naive/Fixed Panel) Assays**

The tumor-agnostic approach prioritizes speed and accessibility. It utilizes a single, pre-designed fixed panel of genes that are known to be frequently mutated in a specific cancer type or across multiple cancers.18 The plasma sample is analyzed directly with this "one-size-fits-all" panel, without any prior knowledge of the patient's specific tumor genetics.39 The

**Guardant Reveal** assay is a prominent commercial example that enhances its fixed genomic panel by also analyzing cancer-specific DNA methylation patterns.18

The key benefits of this approach are speed, with results often available in 7 to 10 days, and its independence from tumor tissue, making it a viable option when a tissue sample is unavailable, inadequate, or was never collected.38 The primary drawback is a potential reduction in sensitivity compared to the tumor-informed method. A patient's tumor may not harbor any of the mutations included on the fixed panel, or the signal from a single detectable mutation may be too low to rise above the assay's noise floor. This approach is also more vulnerable to false-positive results from CHIP, necessitating the use of sophisticated bioinformatic filtering strategies.18

**Table 2: Head-to-Head Comparison of Tumor-Informed vs. Tumor-Agnostic MRD Assays**

| Assay Strategy | Representative Commercial Test(s) | Requirement for Tumor Tissue | Typical Turnaround Time | Underlying Technology | Approach to CHIP Filtering | Key Advantages | Key Limitations |
| :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- |
| **Tumor-Informed** | Natera Signatera, Inivata RaDaR, Haystack MRD | Yes | Initial: 4-6 weeks; Subsequent: 1-2 weeks | WES of tumor followed by personalized mPCR-NGS | Inherently filters CHIP by tracking only confirmed tumor mutations | Highest sensitivity and specificity; personalized to the patient's tumor | Requires adequate tumor tissue; long initial turnaround time; logistical complexity |
| **Tumor-Agnostic** | Guardant Reveal, FoundationOne Tracker | No | 7-10 days | Fixed panel NGS (genomic \+ methylation) | Bioinformatic filtering of known CHIP genes | Fast turnaround time; no tissue required; accessible to more patients | Generally lower sensitivity; risk of false positives from CHIP; may miss patient-specific mutations |

### **2.3 The Bioinformatic Pipeline: From Raw Data to Clinical Insight**

Raw sequencing data is meaningless without a robust bioinformatic pipeline to process it, identify true variants, and filter out myriad sources of technical and biological noise. This computational process is as critical to the assay's performance as the wet-lab chemistry.

The process begins with crucial **pre-analytical steps and quality control**. The method of blood collection is paramount; standard EDTA tubes require processing within hours to prevent white blood cell lysis, which releases large amounts of genomic DNA (gDNA) that can swamp the tiny ctDNA signal. Specialized cell-stabilizing tubes (e.g., Streck tubes) are therefore preferred as they preserve the sample for longer.36 Once the plasma is separated via standardized centrifugation protocols, the raw sequencing data undergoes rigorous quality checks, including the trimming of adapter sequences and the removal of low-quality reads.46

The high-quality reads are then **aligned** to a reference human genome, and specialized **somatic variant callers** (e.g., MuTect, Strelka, TNscope) are deployed to identify potential cancer-associated mutations.46 The central challenge here is that the true ctDNA signal, with a VAF of \<0.1%, is often buried beneath the background sequencing error rate, which can be as high as 0.1-1%.48

**Error suppression** is therefore the most critical bioinformatic step. The primary tool for this is the use of **Unique Molecular Identifiers (UMIs)**. UMIs are short, random DNA sequences (barcodes) that are ligated to each individual cfDNA fragment *before* any PCR amplification takes place.30 After sequencing, all reads that originated from the same initial molecule can be identified by their shared UMI and grouped into a "consensus family." A true mutation will be present in nearly all reads within that family, whereas a random PCR or sequencing error will appear in only one or a few reads and can be computationally discarded. This consensus-based error correction dramatically reduces the technical noise floor and is essential for achieving the sensitivity needed for MRD detection.47 Additional

**in silico polishing** algorithms can further model and subtract known, systematic error patterns to lower the LOD even further.32

Finally, the pipeline must filter out **biological noise**, the most significant source of which is **Clonal Hematopoiesis of Indeterminate Potential (CHIP)**. CHIP is a common, age-related condition where hematopoietic stem cells acquire somatic mutations (e.g., in genes like *DNMT3A*, *TET2*, *ASXL1*). These mutated blood cells release their DNA into the plasma, creating false-positive signals that can be mistaken for cancer.35 The most robust way to eliminate this confounder is to perform paired sequencing of a matched white blood cell (leukocyte) sample from the same patient. Any variant found in both the plasma and the white blood cells is identified as a CHIP mutation and is filtered out from the final analysis.45 Tumor-agnostic assays that do not perform this paired sequencing must rely on less precise methods, such as blacklisting known CHIP-associated genes.45

## **Section 3: Clinical Validation and Application in Solid Tumors**

The translation of liquid biopsy for MRD from a promising technology to a clinically validated tool is advancing rapidly, though progress varies significantly by cancer type. Across numerous solid tumors, a consistent narrative is emerging: the presence of detectable ctDNA after curative-intent therapy is a powerful, pan-cancer harbinger of relapse. This section critically evaluates the clinical evidence in key solid malignancies, focusing on performance metrics and demonstrated utility in guiding patient care.

### **3.1 Colorectal Cancer (CRC): The Vanguard of Solid Tumor MRD**

Colorectal cancer has served as the pioneering field for the clinical development of ctDNA-based MRD assessment. The evidence supporting its utility is more mature here than in any other solid tumor. A primary application is in post-surgical risk stratification, where numerous studies have consistently demonstrated that postoperative ctDNA status is the single most powerful predictor of disease recurrence, significantly outperforming traditional clinicopathologic risk factors like tumor stage or lymph node status.50 Patients who are ctDNA-positive after surgery face a dramatically elevated risk of relapse, with hazard ratios often exceeding 7.0, compared to their ctDNA-negative counterparts.44

This robust prognostic ability has direct clinical implications for guiding adjuvant chemotherapy (ACT). For instance, in stage II CRC, where the overall recurrence risk is low, most patients do not benefit from ACT and are thus potentially overtreated. Postoperative ctDNA negativity effectively identifies a very low-risk population that may be able to safely forgo toxic chemotherapy.17 Conversely, ctDNA positivity identifies the subset of high-risk patients (in both stage II and III disease) who are most likely to derive benefit from ACT.43 This ctDNA-guided strategy is being prospectively evaluated in interventional clinical trials such as PEGASUS, which aims to validate this approach for routine clinical decision-making.44

Beyond the initial postoperative period, longitudinal ctDNA monitoring serves as an ultra-sensitive tool for surveillance. It can detect molecular relapse with a remarkable lead time—often 8 to 12 months—before the recurrence becomes visible on standard radiographic imaging.22 The prospective VICTORI study, for example, reported a median lead time of 198 days.55 This creates a potential therapeutic window to intervene when the recurrent disease burden is still microscopic. This advantage, however, also presents a new clinical dilemma: how to manage a patient with a positive ctDNA test but clean scans. There is currently no standard of care for this "molecular recurrence" state, and proving that early intervention improves survival is the focus of major ongoing trials.55

### **3.2 Non-Small Cell Lung Cancer (NSCLC): A Complex and Evolving Application**

In non-small cell lung cancer, postoperative ctDNA positivity is also a powerful adverse prognostic marker for recurrence and overall survival in patients with early-stage disease.15 The landmark TRACERx study, which deeply profiled NSCLC evolution, showed that ctDNA detection after surgery was highly predictive of subsequent relapse.15 The clinical utility of this finding is being intensely investigated for guiding adjuvant therapy. The advent of highly effective adjuvant treatments, such as immunotherapy and targeted therapies, makes risk stratification particularly valuable. Data from the IMpower010 trial suggested that ctDNA-positive patients derived a substantial benefit from adjuvant atezolizumab (an immune checkpoint inhibitor), whereas the benefit in ctDNA-negative patients was less evident.57 This provides strong rationale for using MRD status to select patients for adjuvant immunotherapy, a strategy being prospectively tested in trials like MERMAID-1.

In the neoadjuvant (pre-surgical) setting, ctDNA dynamics have emerged as an early surrogate for treatment efficacy. In major trials like CheckMate 816 and AEGEAN, clearance of ctDNA after neoadjuvant chemoimmunotherapy was strongly associated with achieving a pathologic complete or major response and with improved long-term survival outcomes.15 This suggests that on-treatment ctDNA monitoring could one day help tailor neoadjuvant regimens in real time.

However, NSCLC presents unique challenges. The amount of ctDNA shed by early-stage lung tumors can be lower than in CRC, posing a greater challenge for assay sensitivity.30 Furthermore, plasma-based liquid biopsy has a known blind spot: it is often falsely negative in patients whose disease recurs solely in the brain, likely due to the blood-brain barrier limiting ctDNA entry into the peripheral circulation.31

### **3.3 Breast Cancer: Monitoring Neoadjuvant Response and Endocrine Resistance**

In breast cancer, ctDNA analysis has demonstrated utility across the disease spectrum. In the neoadjuvant setting, ctDNA dynamics during treatment are predictive of pathologic complete response (pCR), a key surrogate for long-term survival. Patients who successfully clear their ctDNA during neoadjuvant chemotherapy are significantly more likely to achieve pCR, while failure to clear ctDNA is associated with a very high risk of subsequent relapse.31 Post-surgically, ctDNA positivity functions as a strong prognostic marker for metastatic relapse, often detecting it months before imaging can.31

A unique and clinically validated application has emerged in estrogen receptor (ER)-positive metastatic breast cancer. These tumors are often treated with aromatase inhibitors, but they can develop resistance through mutations in the estrogen receptor gene (*ESR1*). The SERENA-6 trial was a landmark study that prospectively tested a liquid biopsy-guided strategy. In this trial, patients on aromatase inhibitors were monitored with liquid biopsies; upon detection of an *ESR1* mutation, they were switched to a different drug (camizestrant). This strategy significantly improved progression-free survival compared to standard care, representing one of the first definitive demonstrations that a proactive treatment change based on a liquid biopsy result improves patient outcomes.59 This success provides a powerful template for future interventional MRD trials.

### **3.4 Other Solid Tumors: Emerging Evidence**

The principle that postoperative ctDNA positivity predicts relapse is proving to be a pan-cancer phenomenon, with compelling evidence emerging in other solid tumors.

* **Melanoma:** In patients with high-risk resected melanoma, the detection of ctDNA (often tracking *BRAF* or *NRAS* mutations) after surgery is strongly associated with recurrence.34 This is being actively investigated as a tool to guide decisions about adjuvant immunotherapy, which is highly effective but also carries significant toxicity.60  
* **Gastrointestinal (GI) Cancers:** In aggressive cancers like gastric, pancreatic, and esophageal cancer, postoperative ctDNA has emerged as a powerful prognostic marker.41 Given the poor prognosis and high recurrence rates in these diseases, an early warning of relapse could be particularly valuable. In pancreatic cancer, ctDNA has been shown to detect recurrence months earlier than conventional imaging.31  
* **Prostate Cancer:** The application of ctDNA for MRD in localized prostate cancer is more complex, as these tumors tend to shed lower levels of ctDNA into the bloodstream.62 However, in the metastatic setting, liquid biopsy is already used for genomic profiling to identify patients eligible for targeted therapies like PARP inhibitors. Its role in the MRD setting after prostatectomy or radiation remains an area of active investigation.64

**Table 3: Summary of Key Clinical Trials for ctDNA-MRD in Solid Tumors**

| Cancer Type | Trial Name/Acronym (Reference) | Patient Population | MRD Assay Used | Primary Question/Endpoint | Key Findings & Clinical Implications |
| :---- | :---- | :---- | :---- | :---- | :---- |
| **Colorectal Cancer** | VICTORI 55 | Stage I-IV resectable CRC | NeXT Personal (Tumor-Informed) | Observational: Prognostic value and lead time of MRD. | ctDNA+ at 4 weeks post-op highly prognostic for recurrence. Median lead time of 198 days over imaging. Highlights value of ultra-sensitive, longitudinal monitoring. |
| **Colorectal Cancer** | PEGASUS 44 | Stage III/High-risk II colon cancer | Guardant Reveal (Tumor-Agnostic) | Interventional: Guide adjuvant therapy based on MRD status. | Post-surgical ctDNA+ status identifies high-risk patients. Early results show ctDNA dynamics may predict response to escalated therapy (FOLFIRI). |
| **Lung Cancer (NSCLC)** | CheckMate 816 15 | Stage IB-IIIA resectable NSCLC | Signatera (Tumor-Informed) | Neoadjuvant setting: Correlate ctDNA clearance with pCR and survival. | ctDNA clearance after neoadjuvant chemo-immunotherapy strongly associated with pCR and improved event-free survival. Establishes ctDNA as an early response biomarker. |
| **Lung Cancer (NSCLC)** | IMpower010 57 | Stage IB-IIIA resected NSCLC | Signatera (Tumor-Informed) | Exploratory analysis: Correlate MRD status with benefit from adjuvant immunotherapy. | ctDNA+ patients derived significant disease-free survival benefit from adjuvant atezolizumab; benefit in ctDNA- patients was not significant. Supports MRD for patient selection. |
| **Breast Cancer** | SERENA-6 59 | Advanced ER+/HER2- breast cancer | Liquid biopsy for *ESR1* mutations | Interventional: Switch therapy based on detection of resistance mutation. | Early switch to camizestrant upon *ESR1* detection significantly improved progression-free survival. First major trial validating a liquid biopsy-guided therapy switch. |

## **Section 4: Clinical Validation and Application in Hematological Malignancies**

In hematological malignancies, MRD is not a new concept; it is an established, cornerstone biomarker that has guided treatment for decades. The innovation of liquid biopsy in this context is not the introduction of MRD itself, but rather the development of a less invasive, potentially more comprehensive method for its measurement. Here, the central question is whether a simple blood test can supplement or even replace the painful and often imperfect standard of bone marrow aspiration.

### **4.1 Acute Leukemias (AML & ALL): A More Systemic and Less Invasive View?**

The standard of care for MRD assessment in acute leukemias has long been the analysis of bone marrow (BM) aspirates, using techniques like multi-parameter flow cytometry (MFC) to identify aberrant cell populations or quantitative PCR (qPCR) to detect specific genetic abnormalities like the *NPM1* mutation.28 While this is the established benchmark, it requires repeated, invasive BM biopsies.

Peripheral blood liquid biopsy, analyzing either ctDNA or circulating tumor cells (CTCs), is emerging as a powerful, less invasive alternative.21 Multiple studies have demonstrated a strong correlation between MRD levels detected in BM and those found in peripheral blood ctDNA.21 More compellingly, evidence suggests that plasma ctDNA may be a biologically superior analyte. In several studies, ctDNA analysis detected MRD in patients who were negative by cellular assays (in both blood and bone marrow) and who later relapsed.69 At very low tumor burdens, ctDNA levels can be quantitatively higher in plasma than in matched cellular compartments, suggesting that ctDNA provides a more holistic measure of the total body disease burden, including extramedullary sites that might be missed by a BM aspirate.69 This counterintuitive finding—that cell-free DNA may be a better marker than the cells themselves—is likely because ctDNA captures the signal of cell death from all disease reservoirs, providing a more integrated picture of tumor clearance. Consequently, ctDNA-based MRD status in acute myeloid leukemia (AML) has been shown to be highly predictive of relapse-free and overall survival, often outperforming traditional BM-based methods.69

### **4.2 Lymphomas (DLBCL & HL): Overcoming Tissue Limitations**

In lymphomas, particularly diffuse large B-cell lymphoma (DLBCL) and classic Hodgkin lymphoma (cHL), tissue biopsies present significant challenges. In cHL, the malignant Hodgkin/Reed-Sternberg cells can be extremely sparse within the biopsied lymph node, making molecular analysis difficult or impossible.36 Furthermore, a single biopsy cannot capture the genetic heterogeneity across different sites of disease.36

Plasma ctDNA analysis elegantly overcomes these limitations by providing a non-invasive, systemic sample for comprehensive mutational profiling.36 Studies have shown that ctDNA levels in lymphoma correlate well with total metabolic tumor volume as measured by PET/CT scans.36 The most powerful application to date is in early response assessment. The dynamics of ctDNA clearance during therapy are a potent predictor of outcome. A rapid and deep drop in ctDNA levels after just one or two cycles of chemotherapy is highly prognostic for a favorable outcome, with some studies showing it to be more predictive than the standard interim PET/CT scan.71 Post-treatment, the persistence of ctDNA is a strong indicator of MRD and impending relapse, while sustained ctDNA clearance is associated with durable remission, making it a valuable tool for guiding consolidation or salvage therapy decisions.72

### **4.3 Multiple Myeloma (MM): Tackling Patchy Disease**

A defining feature of multiple myeloma is its "patchy" or non-uniform infiltration of the bone marrow. This creates a significant sampling problem for the standard BM aspirate; a needle inserted into one area of the pelvis might find no disease, while a large tumor burden exists just centimeters away, leading to a dangerous false-negative MRD result.73

Liquid biopsy offers a compelling solution by providing a systemic sample that should, in theory, reflect the total body tumor burden and overcome the spatial sampling bias of a BM biopsy.73 Several liquid biopsy modalities are being actively investigated in MM:

* **ctDNA Analysis:** NGS-based assays like CAPP-Seq can track MM-specific mutations in cfDNA. Studies have shown a strong correlation between ctDNA levels and BM-based MRD results, with ctDNA negativity being associated with improved progression-free survival.74  
* **Mass Spectrometry (MS):** This novel and highly promising approach does not measure DNA but instead uses high-resolution mass spectrometry to detect the tumor's secreted monoclonal protein (M-protein) in the blood with far greater sensitivity than standard clinical methods like serum immunofixation. This protein-based liquid biopsy may become a leading method for MRD assessment in MM.73  
* **Circulating Plasma Cells (CPCs):** Next-generation flow cytometry can be applied to peripheral blood to detect rare CPCs. However, the number of CPCs in the blood is typically much lower than in the bone marrow, presenting a significant sensitivity challenge that often requires large blood volumes for analysis.73

While none of these blood-based methods have yet replaced bone marrow analysis as the gold standard in MM, they are increasingly viewed as essential complementary tools that provide less invasive, more frequent, and potentially more comprehensive disease monitoring.73

**Table 4: Performance of Liquid Biopsy vs. Bone Marrow Aspiration for MRD in Hematological Malignancies**

| Malignancy | Standard of Care MRD Method | Liquid Biopsy Method | Invasiveness | Concordance with SoC | Key Advantage of Liquid Biopsy | Key Limitation of Liquid Biopsy | Landmark Study/Reference |
| :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- |
| **Acute Myeloid Leukemia (AML)** | MFC or qPCR on Bone Marrow (BM) | ctDNA-NGS (e.g., AML-CAPP-Seq) | High (BM) vs. Low (Blood) | High correlation; ctDNA can be positive when BM is negative. | Higher sensitivity, less invasive, captures total body disease (including extramedullary). | Requires development of personalized assays; CHIP interference. | Nakamura et al. 69, Khodadoust et al. 70 |
| **Diffuse Large B-Cell Lymphoma (DLBCL)** | PET/CT Imaging | ctDNA-NGS | Moderate (PET) vs. Low (Blood) | Good correlation with tumor burden; can be more predictive than PET. | Faster response assessment (after 1-2 cycles), overcomes tissue heterogeneity, less invasive. | Lower ctDNA levels can be a challenge; not yet a replacement for imaging. | Kurtz et al. 71, Roschewski et al. |
| **Multiple Myeloma (MM)** | NGF or NGS on Bone Marrow (BM) | ctDNA-NGS, Mass Spectrometry (MS) | High (BM) vs. Low (Blood) | Significant correlation, but BM remains more sensitive overall. | Overcomes patchy BM sampling error, provides a systemic view, less invasive. | Lower sensitivity than BM for CPCs/ctDNA; MS is still an emerging technology. | Perrot et al. 73, Ladetto et al. 75 |

## **Section 5: Challenges to Clinical Implementation and Future Perspectives**

Liquid biopsy for MRD detection is rapidly moving from a research concept to a clinical tool that is already impacting patient care. However, for this technology to become a true standard of care across oncology, several significant technical, clinical, and economic hurdles must be overcome. Concurrently, the next generation of liquid biopsy technologies, leveraging multi-omics and artificial intelligence, promises to unlock even deeper biological insights and further refine personalized cancer therapy.

### **5.1 Overcoming Hurdles to Routine Adoption**

The path to widespread clinical implementation is fraught with challenges that span the entire testing ecosystem.

* **Technical and Analytical Challenges:** The foremost challenge remains the analytical performance of the assays themselves. Reliably detecting ctDNA at VAFs below 0.01% requires exquisite sensitivity while maintaining near-perfect specificity to avoid both false negatives (which could lead to undertreatment) and false positives (which could lead to overtreatment).19 False negatives can arise from biological factors like low tumor shedding or specific metastatic locations (e.g., the brain), while false positives can be caused by sequencing errors or, most notably, confounding mutations from CHIP.22 Compounding this is a critical lack of  
  **standardization** in the field. There are no universally accepted protocols for blood collection, plasma processing, DNA extraction, assay chemistry, or bioinformatic analysis. This variability makes it exceedingly difficult to compare results from different commercial platforms or academic studies, hindering the development of universal clinical guidelines.7  
* **Clinical and Regulatory Challenges:** Proving that an MRD test is prognostic—that a positive result predicts relapse—is only the first step. The true hurdle is demonstrating **clinical utility**. This requires large-scale, prospective, randomized controlled trials that prove that making a treatment decision based on an MRD result (e.g., escalating or de-escalating therapy) leads to a tangible improvement in patient outcomes, such as longer survival or better quality of life.30 The "lead time" provided by MRD testing also creates a clinical dilemma, as clinicians and patients must decide how to act on molecular evidence of relapse in the absence of radiographic findings.17 Establishing evidence-based guidelines for this new clinical scenario is paramount.  
* **Economic and Accessibility Issues:** Broad adoption hinges on clear regulatory pathways for approval and consistent reimbursement policies from payers. While progress is being made, with Medicare now covering certain MRD tests for specific indications like colorectal cancer, coverage remains a patchwork, limiting patient access.18 Formal cost-effectiveness analyses are needed to demonstrate that the high upfront cost of these advanced tests is justified by downstream savings, such as avoiding ineffective or unnecessary treatments or preventing costly interventions for advanced-stage relapse.2 Finally, the required expertise and technology are currently concentrated in specialized laboratories, which limits global accessibility, particularly in resource-constrained healthcare systems.5

### **5.2 The Next Generation of Liquid Biopsy: Multi-Omics and AI**

The future of liquid biopsy lies in moving beyond the analysis of genomic mutations alone and toward an integrated, multi-omic approach. By combining multiple layers of biological information from a single blood sample, next-generation assays will provide a far more comprehensive and robust picture of a patient's cancer. This includes the integration of:

* **Genomics (ctDNA):** To detect mutations and copy number variations.  
* **Epigenomics (Methylation):** To analyze gene regulation patterns, which can improve detection sensitivity and help identify the tumor's tissue of origin.15  
* **Fragmentomics:** To analyze the size distributions and endpoint patterns of cfDNA fragments. Cancer-derived cfDNA fragments have characteristic size profiles that differ from normal cfDNA, providing an independent, mutation-agnostic signal of malignancy.15  
* **Proteomics and Transcriptomics:** To gain insight into actively expressed proteins and biological pathways, often through the analysis of EVs or CTCs.12

Making sense of this deluge of multi-modal data is impossible without the aid of **Artificial Intelligence (AI) and Machine Learning (ML)**. Sophisticated algorithms are being developed to integrate these diverse data streams with clinical information to build more powerful models for predicting relapse risk and treatment response.5 AI can also be used to learn and filter complex sequencing error patterns, further improving the signal-to-noise ratio, and to automate the interpretation of complex results, providing decision support for clinicians.78

### **5.3 Recommendations and Concluding Remarks: The Path to a New Standard of Care**

The journey of liquid biopsy for MRD detection from a research tool to a standard of care requires a concerted effort from all stakeholders in the oncology community.

* **For Researchers:** The highest priorities should be the development of standardized protocols for sample handling and analysis and the creation of certified reference materials to allow for cross-platform validation. The focus should shift toward multi-omic assays and the development of robust AI/ML models to maximize the information gleaned from every sample.  
* **For Clinicians and Trialists:** The critical need is for well-designed, prospective, randomized interventional trials that use MRD status as a decision point to guide therapy. These trials are the only way to definitively prove clinical utility and must incorporate patient-reported outcomes to assess the impact of MRD-guided care on quality of life.  
* **For Regulators and Payers:** Clear, consistent, and evidence-based frameworks for the evaluation, approval, and reimbursement of MRD tests are essential. Consideration should be given to using ctDNA clearance as a surrogate endpoint in clinical trials to accelerate drug development, but this must be backed by rigorous validation showing a strong link to long-term outcomes like overall survival.58

In conclusion, liquid biopsy for MRD detection is no longer a distant promise but a clinical reality that is actively reshaping patient management in oncology. While formidable challenges in standardization, validation, and implementation persist, the powerful convergence of ultra-sensitive molecular technologies and advanced computational analysis is clearing the path for a new era of precision medicine. This future is one where cancer treatment is not a static prescription but a dynamic, adaptive process, tailored in real time to the molecular state of a patient's disease. The ultimate goal is to intercept relapse at its earliest and most vulnerable stage, thereby personalizing the very definition of a cure.

#### **Reference**

1. Definition of liquid biopsy \- NCI Dictionary of Cancer Terms, accessed July 1, 2025, [https://www.cancer.gov/publications/dictionaries/cancer-terms/def/liquid-biopsy](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/liquid-biopsy)  
2. Liquid biopsies: the future of cancer early detection \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9922467/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9922467/)  
3. What is a liquid biopsy? \- Roche, accessed July 1, 2025, [https://www.roche.com/stories/liquid-biopsy-in-oncology](https://www.roche.com/stories/liquid-biopsy-in-oncology)  
4. Liquid Biopsy: What It Is & Procedure Details \- Cleveland Clinic, accessed July 1, 2025, [https://my.clevelandclinic.org/health/diagnostics/23992-liquid-biopsy](https://my.clevelandclinic.org/health/diagnostics/23992-liquid-biopsy)  
5. Pros and Cons of Liquid Versus Tissue Biopsy in Cancer Research \- iProcess, accessed July 1, 2025, [https://iprocess.net/liquid-biopsy-vs-tissue-biopsy/](https://iprocess.net/liquid-biopsy-vs-tissue-biopsy/)  
6. A Tale of Two Biopsies: Liquid Biopsy vs Tissue Biopsy \- BioChain, accessed July 1, 2025, [https://www.biochain.com/blog/a-tale-of-two-biopsies-liquid-biopsy-vs-tissue-biopsy/](https://www.biochain.com/blog/a-tale-of-two-biopsies-liquid-biopsy-vs-tissue-biopsy/)  
7. Liquid Biopsy versus Traditional Tissue Biopsy \- Integrative Cancer ..., accessed July 1, 2025, [https://integrative-cancer-care.org/liquid-biopsy-versus-traditional-tissue-biopsy/](https://integrative-cancer-care.org/liquid-biopsy-versus-traditional-tissue-biopsy/)  
8. Integrating Liquid Biopsy and ctDNA into Renal Cell Carcinoma Diagnostics \- YouTube, accessed July 1, 2025, [https://www.youtube.com/watch?v=7epXOoyPM54](https://www.youtube.com/watch?v=7epXOoyPM54)  
9. www.biochain.com, accessed July 1, 2025, [https://www.biochain.com/blog/a-tale-of-two-biopsies-liquid-biopsy-vs-tissue-biopsy/\#:\~:text=Liquid%20testing%20also%20uses%20a,in%20the%20body%20(Parnell).](https://www.biochain.com/blog/a-tale-of-two-biopsies-liquid-biopsy-vs-tissue-biopsy/#:~:text=Liquid%20testing%20also%20uses%20a,in%20the%20body%20\(Parnell\).)  
10. The Role of Circulating Tumor Cells as a Liquid Biopsy for Cancer: Advances, Biology, Technical Challenges, and Clinical Relevance \- MDPI, accessed July 1, 2025, [https://www.mdpi.com/2072-6694/16/7/1377](https://www.mdpi.com/2072-6694/16/7/1377)  
11. Recent Advancements in the Application of Circulating Tumor DNA as Biomarkers for Early Detection of Cancers | ACS Biomaterials Science & Engineering, accessed July 1, 2025, [https://pubs.acs.org/doi/10.1021/acsbiomaterials.4c00606](https://pubs.acs.org/doi/10.1021/acsbiomaterials.4c00606)  
12. Liquid Biopsy: The Challenges of a Revolutionary Approach in ..., accessed July 1, 2025, [https://www.mdpi.com/1422-0067/26/11/5013](https://www.mdpi.com/1422-0067/26/11/5013)  
13. Liquid biopsy: A new tool for identifying and monitoring cancer \- UChicago Medicine, accessed July 1, 2025, [https://www.uchicagomedicine.org/forefront/cancer-articles/liquid-biopsies](https://www.uchicagomedicine.org/forefront/cancer-articles/liquid-biopsies)  
14. Liquid Biopsy Test | The Iowa Clinic, accessed July 1, 2025, [https://www.iowaclinic.com/specialties/cancer-care/hematology-oncology/immunotherapy/liquid-biopsy-test/](https://www.iowaclinic.com/specialties/cancer-care/hematology-oncology/immunotherapy/liquid-biopsy-test/)  
15. Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring \- ASCO Publications, accessed July 1, 2025, [https://ascopubs.org/doi/10.1200/EDBK-25-481114](https://ascopubs.org/doi/10.1200/EDBK-25-481114)  
16. Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review \- PubMed Central, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10448395/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10448395/)  
17. Review Finds Room for Improvement in MRD Detection Via Liquid Biopsy for Solid Tumor Cancers \- American Journal of Managed Care, accessed July 1, 2025, [https://www.ajmc.com/view/review-finds-room-for-improvement-in-mrd-detection-via-liquid-biopsy-for-solid-tumor-cancers](https://www.ajmc.com/view/review-finds-room-for-improvement-in-mrd-detection-via-liquid-biopsy-for-solid-tumor-cancers)  
18. Understanding Molecular Residual Disease (MRD) in ... \- BLOODPAC, accessed July 1, 2025, [https://www.bloodpac.org/bloodpac-blog/mrd-solid-tumors](https://www.bloodpac.org/bloodpac-blog/mrd-solid-tumors)  
19. What are the Differences Between ctDNA and CTC? \- Paragon Genomics, accessed July 1, 2025, [https://www.paragongenomics.com/what-are-the-differences-between-ctdna-and-ctc/](https://www.paragongenomics.com/what-are-the-differences-between-ctdna-and-ctc/)  
20. Cancer Liquid Biopsy Research | NGS to detect tumor-derived biomarkers \- Illumina, accessed July 1, 2025, [https://www.illumina.com/areas-of-interest/cancer/research/applications/liquid-biopsy-research.html](https://www.illumina.com/areas-of-interest/cancer/research/applications/liquid-biopsy-research.html)  
21. The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8909350/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8909350/)  
22. Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy ..., accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10850354/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850354/)  
23. GRAIL: Homepage, accessed July 1, 2025, [https://grail.com/](https://grail.com/)  
24. www.cancer.gov, accessed July 1, 2025, [https://www.cancer.gov/publications/dictionaries/cancer-terms/def/minimal-residual-disease\#:\~:text=(MIH%2Dnih%2Dmul%20ree,among%20one%20million%20normal%20cells.](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/minimal-residual-disease#:~:text=\(MIH%2Dnih%2Dmul%20ree,among%20one%20million%20normal%20cells.)  
25. Definition of minimal residual disease \- NCI Dictionary of Cancer Terms, accessed July 1, 2025, [https://www.cancer.gov/publications/dictionaries/cancer-terms/def/minimal-residual-disease](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/minimal-residual-disease)  
26. What is minimal residual disease (MRD)? \- MD Anderson Cancer Center, accessed July 1, 2025, [https://www.mdanderson.org/cancerwise/what-is-minimal-residual-disease--mrd--multiple-myeloma-lymphoma-leukemia-patients.h00-159383523.html](https://www.mdanderson.org/cancerwise/what-is-minimal-residual-disease--mrd--multiple-myeloma-lymphoma-leukemia-patients.h00-159383523.html)  
27. Measurable Residual Disease (MRD) \- Leukemia & Lymphoma Society, accessed July 1, 2025, [https://www.lls.org/sites/default/files/2024-03/FS35\_Measurable\_Residual\_Disease\_2024.pdf](https://www.lls.org/sites/default/files/2024-03/FS35_Measurable_Residual_Disease_2024.pdf)  
28. Minimal Residual Disease (MRD) \- Leukemia & Lymphoma Society, accessed July 1, 2025, [https://www.lls.org/sites/default/files/National/USA/Pdf/Publications/FS35\_MRD\_Final\_2019.pdf](https://www.lls.org/sites/default/files/National/USA/Pdf/Publications/FS35_MRD_Final_2019.pdf)  
29. Approaches to and the use of MRD in ALL \- YouTube, accessed July 1, 2025, [https://www.youtube.com/watch?v=LaxeluTnwqs](https://www.youtube.com/watch?v=LaxeluTnwqs)  
30. Liquid Biopsy, or Circulating Tumor Cells, May Help the Diagnosis of Early-Stage Cancer and Minimal Residual Disease Detection \- Oncology Practice Management, accessed July 1, 2025, [https://oncpracticemanagement.com/issues/2018/april-2018-vol-8-no-4/liquid-biopsy-or-circulating-tumor-cells-may-help-the-diagnosis-of-early-stage-cancer-and-minimal-residual-disease-detection](https://oncpracticemanagement.com/issues/2018/april-2018-vol-8-no-4/liquid-biopsy-or-circulating-tumor-cells-may-help-the-diagnosis-of-early-stage-cancer-and-minimal-residual-disease-detection)  
31. Minimal residual disease (MRD) detection in solid tumors ... \- Frontiers, accessed July 1, 2025, [https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2023.1172108/full](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2023.1172108/full)  
32. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8976700/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8976700/)  
33. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease | Cancer Discovery \- AACR Journals, accessed July 1, 2025, [https://aacrjournals.org/cancerdiscovery/article/11/12/2968/674721/Detecting-Liquid-Remnants-of-Solid-Tumors](https://aacrjournals.org/cancerdiscovery/article/11/12/2968/674721/Detecting-Liquid-Remnants-of-Solid-Tumors)  
34. Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma \- MDPI, accessed July 1, 2025, [https://www.mdpi.com/1422-0067/26/2/861](https://www.mdpi.com/1422-0067/26/2/861)  
35. Genomic approaches to cancer and minimal residual disease ..., accessed July 1, 2025, [https://jitc.bmj.com/content/11/6/e006284](https://jitc.bmj.com/content/11/6/e006284)  
36. Liquid biopsy in hematological malignancies: current and future applications \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10157039/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10157039/)  
37. Full article: Clinical application of molecular residual disease detection by circulation tumor DNA in solid cancers and a comparison of technologies, accessed July 1, 2025, [https://www.tandfonline.com/doi/full/10.1080/15384047.2023.2274123](https://www.tandfonline.com/doi/full/10.1080/15384047.2023.2274123)  
38. Tumor-naive versus tumor-informed approaches to MRD testing \- Haystack MRD, accessed July 1, 2025, [https://haystackmrd.com/tumor-naive-versus-tumor-informed-approaches-to-mrd-testing/](https://haystackmrd.com/tumor-naive-versus-tumor-informed-approaches-to-mrd-testing/)  
39. Clinical application of molecular residual disease detection by circulation tumor DNA in solid cancers and a comparison of technologies: review article \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10653633/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10653633/)  
40. Liquid Biopsy Techniques Test Lung Cancer MRD Level, accessed July 1, 2025, [https://www.targetedonc.com/view/liquid-biopsy-techniques-test-lung-cancer-mrd-level](https://www.targetedonc.com/view/liquid-biopsy-techniques-test-lung-cancer-mrd-level)  
41. (PDF) Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay \- ResearchGate, accessed July 1, 2025, [https://www.researchgate.net/publication/373264115\_Monitoring\_of\_gastrointestinal\_carcinoma\_via\_molecular\_residual\_disease\_with\_circulating\_tumor\_DNA\_using\_a\_tumor-informed\_assay](https://www.researchgate.net/publication/373264115_Monitoring_of_gastrointestinal_carcinoma_via_molecular_residual_disease_with_circulating_tumor_DNA_using_a_tumor-informed_assay)  
42. Tumor-Informed Versus Plasma-Only Liquid Biopsy Assay in a Patient With Multiple Primary Malignancies | JCO Precision Oncology \- ASCO Publications, accessed July 1, 2025, [https://ascopubs.org/doi/10.1200/PO.21.00298](https://ascopubs.org/doi/10.1200/PO.21.00298)  
43. Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal ..., accessed July 1, 2025, [https://www.mdpi.com/2073-4425/16/1/71](https://www.mdpi.com/2073-4425/16/1/71)  
44. Studies confirm the promise of ctDNA for MRD assessment in colorectal cancer, but limitations remain \- ESMO Daily Reporter, accessed July 1, 2025, [https://dailyreporter.esmo.org/esmo-congress-2023/highlights-from-esmo-2023/studies-confirm-the-promise-of-ctdna-for-mrd-assessment-in-colorectal-cancer-but-limitations-remain](https://dailyreporter.esmo.org/esmo-congress-2023/highlights-from-esmo-2023/studies-confirm-the-promise-of-ctdna-for-mrd-assessment-in-colorectal-cancer-but-limitations-remain)  
45. Critical Factors in the Analytical Work Flow of Circulating Tumor DNA-Based Molecular Profiling \- Oxford Academic, accessed July 1, 2025, [https://academic.oup.com/clinchem/article/70/1/220/7505412](https://academic.oup.com/clinchem/article/70/1/220/7505412)  
46. The Bioinformatics Pipeline for Liquid Biopsy \- Number Analytics, accessed July 1, 2025, [https://www.numberanalytics.com/blog/bioinformatics-pipeline-liquid-biopsy](https://www.numberanalytics.com/blog/bioinformatics-pipeline-liquid-biopsy)  
47. Processing UMI Datasets at High Accuracy and Efficiency with the Sentieon ctDNA Analysis Pipeline \- bioRxiv, accessed July 1, 2025, [https://www.biorxiv.org/content/10.1101/2022.06.03.494742v3.full.pdf](https://www.biorxiv.org/content/10.1101/2022.06.03.494742v3.full.pdf)  
48. Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: a narrative review \- PubMed Central, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12000943/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12000943/)  
49. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review), accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10152452/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10152452/)  
50. Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8507967/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8507967/)  
51. The Role of Circulating Tumor DNA in Evaluating Minimal Residual Disease in Luminal Gastrointestinal Malignancies \- Hematology & Oncology \- Millennium Medical Publishing, accessed July 1, 2025, [https://www.hematologyandoncology.net/archives/july-2022/the-role-of-circulating-tumor-dna-in-evaluating-minimal-residual-disease-in-luminal-gastrointestinal-malignancies/](https://www.hematologyandoncology.net/archives/july-2022/the-role-of-circulating-tumor-dna-in-evaluating-minimal-residual-disease-in-luminal-gastrointestinal-malignancies/)  
52. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11021841/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11021841/)  
53. U.S. Minimal Residual Disease Testing Market Report, 2033, accessed July 1, 2025, [https://www.grandviewresearch.com/industry-analysis/us-minimal-residual-disease-testing-market-report](https://www.grandviewresearch.com/industry-analysis/us-minimal-residual-disease-testing-market-report)  
54. GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing CtDNA Diagnostics \- Colorectal Cancer | ClinicalTrials.gov, accessed July 1, 2025, [https://clinicaltrials.gov/ct2/show/NCT06111105](https://clinicaltrials.gov/ct2/show/NCT06111105)  
55. A Liquid Biopsy-based Assay Could Detect Recurrence Prior to ..., accessed July 1, 2025, [https://www.aacr.org/about-the-aacr/newsroom/news-releases/a-liquid-biopsy-based-assay-could-detect-recurrence-prior-to-imaging-in-patients-with-resectable-colorectal-cancer/](https://www.aacr.org/about-the-aacr/newsroom/news-releases/a-liquid-biopsy-based-assay-could-detect-recurrence-prior-to-imaging-in-patients-with-resectable-colorectal-cancer/)  
56. Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay. | Journal of Clinical Oncology \- ASCO Publications, accessed July 1, 2025, [https://ascopubs.org/doi/10.1200/JCO.2024.42.16\_suppl.e15625](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e15625)  
57. A comprehensive overview of minimal residual disease in the ..., accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12166047/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12166047/)  
58. Liquid biopsy in advanced and metastatic breast cancer: translating prognostic value to clinical implementation \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12079236/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12079236/)  
59. Switch to Experimental Drug after Liquid Biopsy Detection of Breast Cancer Recurrence Improves Outcomes | Newsroom | Weill Cornell Medicine, accessed July 1, 2025, [https://news.weill.cornell.edu/news/2025/06/switch-to-experimental-drug-after-liquid-biopsy-detection-of-breast-cancer-recurrence](https://news.weill.cornell.edu/news/2025/06/switch-to-experimental-drug-after-liquid-biopsy-detection-of-breast-cancer-recurrence)  
60. Liquid biopsy for diagnostic and prognostic evaluation of melanoma \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11327088/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11327088/)  
61. State of the Art: ctDNA in Upper Gastrointestinal Malignancies \- MDPI, accessed July 1, 2025, [https://www.mdpi.com/2072-6694/15/5/1379](https://www.mdpi.com/2072-6694/15/5/1379)  
62. Article: The Utility of Liquid Biopsy in Oncology Clinical Trials \- Medpace, accessed July 1, 2025, [https://www.medpace.com/wp-content/uploads/2023/03/Article-The-Utility-of-Liquid-Biopsy-in-Oncology-Clinical-Trials.pdf](https://www.medpace.com/wp-content/uploads/2023/03/Article-The-Utility-of-Liquid-Biopsy-in-Oncology-Clinical-Trials.pdf)  
63. Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9265840/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9265840/)  
64. Discovering the mystery of MRD with Liquid Biopsy | 4baseCare, accessed July 1, 2025, [https://4basecare.com/discovering-the-mystery-of-mrd-with-liquid-biopsy/](https://4basecare.com/discovering-the-mystery-of-mrd-with-liquid-biopsy/)  
65. The Next Wave of Cancer Care: ctDNA's Emerging Role \- Targeted Oncology, accessed July 1, 2025, [https://www.targetedonc.com/view/the-next-wave-of-cancer-care-ctdna-s-emerging-role](https://www.targetedonc.com/view/the-next-wave-of-cancer-care-ctdna-s-emerging-role)  
66. The present and future of measurable residual disease testing in acute myeloid leukemia, accessed July 1, 2025, [https://haematologica.org/article/view/haematol.2022.282034](https://haematologica.org/article/view/haematol.2022.282034)  
67. The Minimal Residual Disease Using Liquid Biopsies in ... \- MDPI, accessed July 1, 2025, [https://www.mdpi.com/2072-6694/14/5/1310](https://www.mdpi.com/2072-6694/14/5/1310)  
68. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11210172/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11210172/)  
69. Message from the void: MRD analysis from ctDNA | Blood ..., accessed July 1, 2025, [https://ashpublications.org/blood/article/133/25/2631/273885/Message-from-the-void-MRD-analysis-from-ctDNA](https://ashpublications.org/blood/article/133/25/2631/273885/Message-from-the-void-MRD-analysis-from-ctDNA)  
70. Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival | Blood, accessed July 1, 2025, [https://ashpublications.org/blood/article/144/Supplement%201/2955/532815/Circulating-Tumor-DNA-ctDNA-Enables-Superior-and](https://ashpublications.org/blood/article/144/Supplement%201/2955/532815/Circulating-Tumor-DNA-ctDNA-Enables-Superior-and)  
71. Liquid biopsy in hematological malignancies: current and future ..., accessed July 1, 2025, [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157039/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157039/)  
72. The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell Lymphoma | medRxiv, accessed July 1, 2025, [https://www.medrxiv.org/content/10.1101/2025.04.14.25325806v1.full-text](https://www.medrxiv.org/content/10.1101/2025.04.14.25325806v1.full-text)  
73. Liquid biopsy and blood-based minimal residual disease evaluation ..., accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10229300/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10229300/)  
74. 160 Circulating tumor DNA for measurable residual disease (MRD) detection in multiple myeloma patients undergoing CAR T-cell therapy | Journal for ImmunoTherapy of Cancer, accessed July 1, 2025, [https://jitc.bmj.com/content/11/Suppl\_1/A179](https://jitc.bmj.com/content/11/Suppl_1/A179)  
75. Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes–A feasibility study \- PubMed Central, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10218758/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10218758/)  
76. Liquid Biopsies as Non-Invasive Tools for Mutation Profiling in ..., accessed July 1, 2025, [https://www.mdpi.com/1422-0067/25/10/5208](https://www.mdpi.com/1422-0067/25/10/5208)  
77. Editorial: Liquid biopsies in hematological malignancies \- Frontiers, accessed July 1, 2025, [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1440394/epub](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1440394/epub)  
78. Editorial: The emerging role of liquid biopsies in hematologic disorders \- Frontiers, accessed July 1, 2025, [https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1437621/full](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1437621/full)  
79. economic-evaluation-of-multi-indication-health-technologies-proposed-approaches.docx \- NICE, accessed July 1, 2025, [https://www.nice.org.uk/Media/Default/About/what-we-do/HTA%20Lab/economic-evaluation-of-multi-indication-health-technologies-proposed-approaches.docx](https://www.nice.org.uk/Media/Default/About/what-we-do/HTA%20Lab/economic-evaluation-of-multi-indication-health-technologies-proposed-approaches.docx)  
80. Integrative analysis of multi-omics data for liquid biopsy \- PMC, accessed July 1, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9938261/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9938261/)  
81. Liquid biopsies and minimal residual disease in myeloid malignancies \- Frontiers, accessed July 1, 2025, [https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1164017/full](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1164017/full)  
82. AI-enabled whole exome & transcriptome liquid biopsy addressing MCED, MRD, and therapy selection on a single platform | Caris Life Sciences, accessed July 1, 2025, [https://www.carislifesciences.com/research/publications/ai-enabled-whole-exome-transcriptome-liquid-biopsy-addressing-mced-mrd-and-therapy-selection-on-a-single-platform/](https://www.carislifesciences.com/research/publications/ai-enabled-whole-exome-transcriptome-liquid-biopsy-addressing-mced-mrd-and-therapy-selection-on-a-single-platform/)  
83. Tracking Minimal Residual Disease with Liquid Biopsy \- Clinomics Europe, accessed July 1, 2025, [https://clinomicseurope.com/tracking-minimal-residual-disease-with-liquid-biopsy/](https://clinomicseurope.com/tracking-minimal-residual-disease-with-liquid-biopsy/)  
84. QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships \- Stock Titan, accessed July 1, 2025, [https://www.stocktitan.net/news/QGEN/qiagen-expands-portfolio-for-minimal-residual-disease-mrd-testing-in-11ry3a58qljf.html](https://www.stocktitan.net/news/QGEN/qiagen-expands-portfolio-for-minimal-residual-disease-mrd-testing-in-11ry3a58qljf.html)
